

# Reisa Sperling

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10811457/publications.pdf>

Version: 2024-02-01

33  
papers

13,491  
citations

257450  
24  
h-index

395702  
33  
g-index

34  
all docs

34  
docs citations

34  
times ranked

15007  
citing authors

#	ARTICLE	IF	CITATIONS
1	Longitudinal Trajectories of Participant- and Study Partner-Rated Cognitive Decline, in Relation to Alzheimer's Disease Biomarkers and Mood Symptoms. <i>Frontiers in Aging Neuroscience</i> , 2021, 13, 806432.	3.4	7
2	Cerebral amyloid angiopathy and Alzheimer disease – one peptide, two pathways. <i>Nature Reviews Neurology</i> , 2020, 16, 30-42.	10.1	407
3	Associative memory and in vivo brain pathology in asymptomatic presenilin-1 E280A carriers. <i>Neurology</i> , 2020, 95, e1312-e1321.	1.1	7
4	Amyloid imaging of dutch-type hereditary cerebral amyloid angiopathy carriers. <i>Annals of Neurology</i> , 2019, 86, 616-625.	5.3	22
5	Dementia is not synonymous with Alzheimer's disease. <i>Science Translational Medicine</i> , 2019, 11, .	12.4	11
6	NIA's Research Framework: Toward a biological definition of Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2018, 14, 535-562.	0.8	5,861
7	Biomarker pattern of ARIA-E participants in phase 3 randomized clinical trials with bapineuzumab. <i>Neurology</i> , 2018, 90, e877-e886.	1.1	28
8	Clinical Evaluation of Amyloid-Related Imaging Abnormalities in Bapineuzumab Phase III Studies. <i>Journal of Alzheimer's Disease</i> , 2018, 66, 1409-1424.	2.6	22
9	Long-Term Follow Up of Patients with Mild-to-Moderate Alzheimer's Disease Treated with Bapineuzumab in a Phase III, Open-Label, Extension Study. <i>Journal of Alzheimer's Disease</i> , 2018, 64, 689-707.	2.6	15
10	Hierarchical Organization of Tau and Amyloid Deposits in the Cerebral Cortex. <i>JAMA Neurology</i> , 2017, 74, 813.	9.0	61
11	Tau and amyloid $\beta$ proteins distinctively associate to functional network changes in the aging brain. <i>Alzheimer's and Dementia</i> , 2017, 13, 1261-1269.	0.8	90
12	On the path to 2025: understanding the Alzheimer's disease continuum. <i>Alzheimer's Research and Therapy</i> , 2017, 9, 60.	6.2	316
13	Challenges, solutions, and recommendations for Alzheimer's disease combination therapy. , 2016, 12, 623-630.		39
14	Testing and disclosures related to amyloid imaging and Alzheimer's disease: Common questions and fact sheet summary. <i>Alzheimer's and Dementia</i> , 2016, 12, 510-515.	0.8	23
15	Tau Positron Emission Tomographic Imaging in the Lewy Body Diseases. <i>JAMA Neurology</i> , 2016, 73, 1334.	9.0	182
16	Tau positron emission tomographic imaging in aging and early Alzheimer disease. <i>Annals of Neurology</i> , 2016, 79, 110-119.	5.3	778
17	A Conceptualization of the Utility of Subjective Cognitive Decline in Clinical Trials of Preclinical Alzheimer's Disease. <i>Journal of Molecular Neuroscience</i> , 2016, 60, 354-361.	2.3	37
18	In Vivo Tau, Amyloid, and Gray Matter Profiles in the Aging Brain. <i>Journal of Neuroscience</i> , 2016, 36, 7364-7374.	3.6	153

#	ARTICLE	IF	CITATIONS
19	Preclinical Alzheimer's disease: Definition, natural history, and diagnostic criteria. <i>Alzheimer's and Dementia</i> , 2016, 12, 292-323.	0.8	1,318
20	Understanding Conflicting Neuropathological Findings in Patients Clinically Diagnosed as Having Alzheimer Dementia. <i>JAMA Neurology</i> , 2015, 72, 1106.	9.0	13
21	Amyloid- $\beta^{2 \times 11}$ C-PiB-PET imaging results from 2 randomized bapineuzumab phase 3 AD trials. <i>Neurology</i> , 2015, 85, 692-700.	1.1	136
22	Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease. <i>New England Journal of Medicine</i> , 2014, 370, 322-333.	27.0	1,613
23	The Evolution of Preclinical Alzheimer's Disease: Implications for Prevention Trials. <i>Neuron</i> , 2014, 84, 608-622.	8.1	568
24	Promising developments in neuropsychological approaches for the detection of preclinical Alzheimer's disease: a selective review. <i>Alzheimer's Research and Therapy</i> , 2013, 5, 58.	6.2	146
25	Inflammatory cerebral amyloid angiopathy and amyloid-modifying therapies: Variations on the Same ARIA?. <i>Annals of Neurology</i> , 2013, 73, 439-441.	5.3	27
26	Amyloid-related imaging abnormalities in patients with Alzheimer's disease treated with bapineuzumab: a retrospective analysis. <i>Lancet Neurology</i> , The, 2012, 11, 241-249.	10.2	390
27	The potential of functional MRI as a biomarker in early Alzheimer's disease. <i>Neurobiology of Aging</i> , 2011, 32, S37-S43.	3.1	134
28	Reliability of functional magnetic resonance imaging associative encoding memory paradigms in non-demented elderly adults. <i>Human Brain Mapping</i> , 2011, 32, 2027-2044.	3.6	27
29	Hippocampal Hyperactivation Associated with Cortical Thinning in Alzheimer's Disease Signature Regions in Non-Demented Elderly Adults. <i>Journal of Neuroscience</i> , 2011, 31, 17680-17688.	3.6	201
30	Functional MRI Studies of Associative Encoding in Normal Aging, Mild Cognitive Impairment, and Alzheimer's Disease. <i>Annals of the New York Academy of Sciences</i> , 2007, 1097, 146-155.	3.8	210
31	Two macroscopic and microscopic brain imaging studies of human hippocampus in early Alzheimer's disease and schizophrenia research. <i>Statistics in Medicine</i> , 2004, 23, 327-350.	1.6	5
32	Putting names to faces:. <i>NeuroImage</i> , 2003, 20, 1400-1410.	4.2	319
33	Functional MRI detection of pharmacologically induced memory impairment. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2002, 99, 455-460.	7.1	198